Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654882 · ClinicalTrials.gov registry record · Phase 3
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
A Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA), sponsored by Duke University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 5
- Study locations
NCT06654882 is a Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA) that is actively recruiting participants, run by Duke University. The registered enrollment target is 400 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06654882, a Phase 3 study of Polyarticular Course Juvenile Idiopathic Arthritis (JIA), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Tocilizumab
- DRUG TNFi (Tumor Necrosis Factor inhibitor) medication
- DRUG Tofacitinib
Study Locations (5)
California
- University of California San Francisco Pediatric Rheumatology - San Francisco
Florida
- University of Florida - Gainesville
New Jersey
- Hackensack University Medical Center - Joseph M. Sanzari Children's Hospital - Hackensack
Ohio
- Nationwide Children's Hospital - Columbus
North Rhine-Westphalia
- Asklepios Children's Hospital - Sankt Augustin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06654882
The ClinicalTrials.gov registry entry for NCT06654882 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polyarticular Course Juvenile Idiopathic Arthritis (JIA) appearing as the primary indexed condition, and to 4 interventions - of which Abatacept is the first listed.
NCT06654882 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06654882 about?
NCT06654882 is a clinical study titled "Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis". This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages cor...
What is the current status of trial NCT06654882?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2026-01-09. Estimated completion is 2026-12.
What conditions does trial NCT06654882 study?
This clinical trial studies the following conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA).
What interventions are being tested in trial NCT06654882?
The interventions under investigation include: Abatacept (DRUG), Tocilizumab (DRUG), TNFi (Tumor Necrosis Factor inhibitor) medication (DRUG), Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT06654882?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06654882 being conducted?
This trial has 5 study locations across California, Florida, New Jersey, Ohio, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.